NICE approves daratumumab monotherapy for relapsed and refractory myeloma patients
The National Institute of Health and Care Excellence (NICE) has approved the use of daratumumab (Darzalex®) monotherapy as a treatment for relapsed and refractory myeloma patients. This treatment will be made available through the Cancer Drugs Fund (CDF) to patients in England and Wales who have received 3 prior treatments, including a proteasome inhibitor and…